Building on our reported in vivo evidence demonstrating the inhibitory function of myeloid CCN3 in atherosclerosis [16], we tested our hypothesis that myeloid CCN3 mitigates aortic valve calcification, thus a protective factor against CAVD. This evidence concerns the gene CCN3 and congenital bilateral aplasia of vas deferens from CFTR mutation.